



<b>Form PT 9-1449</b> (REV. 8-83)		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Attorney Docket</b> 2003946-0049		<b>In re Application No.</b> 09/963,316	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				<b>Applicant:</b> Imai, et al.			
				<b>Filing Date:</b> September 25, 2001		<b>Group:</b> 1644	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner's</b> <b>Initials</b>	<b>U.S. Patent No.</b>	<b>Applicant</b>	<b>Issue Date</b>		<b>Class</b>	<b>Subclass</b>	
<b>U.S. PATENT APPLICATIONS</b>							
<b>Examiner's</b> <b>Initials:</b>	<b>Serial Number:</b>	<b>Applicant:</b>	<b>Filing Date:</b>		<b>Group:</b>	<b>Art Unit:</b>	
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Examiner's</b> <b>Initials</b>	<b>Document No.</b>	<b>Country</b>	<b>International</b> <b>Publication Date</b>	<b>Translation</b>			
				<b>Yes</b>	<b>No</b>		
<b>OTHER DOCUMENTS</b>							
<b>Examiner's</b> <b>Initials</b>	<b>Citation (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	A. Campbell <i>et al.</i> , "General Properties and Applications of Monoclonal Antibodies" in Monoclonal Antibody Technology, 1985, pages 1-32.						
	J.K. Harrison <i>et al.</i> , "Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia", Proc. Natl. Acad. Sci. USA, 1998, 95: 10896-10901						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b> 4/6/05			
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to t applicant.							